Foundational Principles of Antibiotic Stewardship & PK/PD in Critical Care
Lesson Objective
Apply epidemiology, pathophysiology, and social factors to optimize antibiotic use and dosing in the ICU.
I. Epidemiology and Incidence of Antibiotic Resistance in Critical Care
Summary: Antibiotic resistance in the ICU is driven by global trends, unit-specific practices, and surveillance limitations. Understanding local and regional patterns informs empirical choices and stewardship priorities.
1.1 Global Trends and Regional Variability
- High-income ICUs report 20–30% carbapenem-resistant Enterobacterales; low- and middle-income units often exceed 50%.
- ESBL producers dominate in Asia/Latin America; VRE is rising in Europe and North America.
- Drivers: antibiotic overuse, infection control resources, formulary access.
1.2 ICU-Specific Resistance Patterns and Drivers
- Risk factors: prolonged ventilation, central lines, immunosuppression, broad-spectrum exposure.
- Up to 50% of ICU antibiotics are inappropriate in spectrum or duration.
- Common MDR pathogens: Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae.
1.3 Surveillance Methods and Data Interpretation
- Phenotypic cultures vs. rapid molecular assays (PCR, MALDI-TOF) to detect resistance genes.
- Unit-specific antibiograms guide empiric therapy but may lag emerging trends.
- Statistical tools (funnel plots, CUSUM) track resistance clusters over time.
Key Clinical Pearls
- Tailor empiric regimens to local ICU antibiogram, not national averages.
- Rapid diagnostics can shorten broad-spectrum exposure by 24–48 hours.
II. Pathophysiologic Basis for Altered Antimicrobial PK/PD in Critical Illness
Summary: Sepsis and organ dysfunction alter absorption, distribution, metabolism, and excretion, affecting drug exposure and efficacy. PK/PD principles guide dosing adjustments.
2.1 Pharmacokinetic Alterations
2.1.1 Augmented Renal Clearance (ARC)
- Hyperdynamic GFR (>130 mL/min/1.73 m²) leads to subtherapeutic β-lactam and aminoglycoside levels.
- Action: measure 8–24 h CrCl and increase dose or frequency accordingly.
2.1.2 Hypoalbuminemia and Distribution Changes
- Low albumin increases free fraction of protein-bound drugs (e.g., ceftriaxone).
- Interpret TDM on unbound concentrations when possible.
2.1.3 Metabolic and Excretory Variations
- Hepatic hypoperfusion reduces phase I/II metabolism (e.g., linezolid half-life ↑).
- CRRT removes hydrophilic agents unpredictably; adjust per effluent rate.
2.2 Pharmacodynamic Considerations
Key Clinical Pearls
- Continuous β-lactam infusions can improve outcomes in severe infections.
- Always reassess volume status and organ function before dose escalation.
III. Impact of Chronic Diseases on PK/PD and Stewardship
Summary: Pre-existing renal and hepatic dysfunction alter drug clearance and toxicity risk. Polypharmacy elevates interaction potential, requiring integrated stewardship.
3.1 Renal Dysfunction
- Creatinine Clearance Estimation: Cockcroft-Gault may overestimate GFR in low-muscle ICU patients. Preferred: measured urinary CrCl or Bayesian dosing software for vancomycin, fluoroquinolones.
- Renal Replacement Therapy (RRT): CRRT removes small hydrophilic drugs. For vancomycin, a typical approach is loading with 25–30 mg/kg, then maintenance of 15–20 mg/kg q24–48h, adjusted by effluent flow and TDM.
3.2 Hepatic Impairment
- Metabolism Alterations: Reduced CYP450 activity prolongs agents like erythromycin. Consider a 25–50% dose reduction for linezolid or fluconazole in Child-Pugh Class C.
- Monitoring: Track LFTs and drug-specific toxicities (e.g., linezolid-induced thrombocytopenia).
| Antimicrobial | Renal Impairment / CRRT | Hepatic Impairment (Severe) |
|---|---|---|
| Vancomycin | Dose adjust for CrCl <50; TDM is essential. CRRT requires higher doses. | No adjustment typically needed. |
| Piperacillin-Tazobactam | Dose adjust for CrCl <40. Use extended infusions. Significant removal by CRRT. | No adjustment typically needed. |
| Linezolid | No dose adjustment needed for renal failure or CRRT. | Consider 25-50% dose reduction in Child-Pugh C due to reduced metabolism. |
| Ceftriaxone | No dose adjustment needed due to dual elimination pathway. | No dose adjustment needed. High protein binding is a key consideration. |
| Metronidazole | No dose adjustment needed for parent drug; metabolites may accumulate. | Dose reduce by 50% for severe (Child-Pugh C) impairment. |
Key Clinical Pearls
- In unstable renal function, use Bayesian TDM tools over static nomograms.
- Adjust hepatic-cleared drugs preemptively in patients with shock liver or cirrhosis.
IV. Social Determinants of Health Influencing Antimicrobial Use
Summary: Medication access, health literacy, and socioeconomic status shape adherence and prescribing. Multidisciplinary strategies can mitigate disparities.
4.1 Medication Access and Formulary Constraints
- Shortages and insurance restrict spectrum; stewardship must balance cost vs. adequacy.
- Advocate for patient assistance and institutional formulary updates.
4.2 Health Literacy and Patient Education
- Use teach-back methods and simplified schedules to improve oral regimen adherence.
- Involve bedside pharmacists in discharge rounds for counseling.
4.3 Socioeconomic Factors and Adherence Challenges
- Out-of-pocket costs drive early discontinuation of oral therapy.
- Collaborate with social work to secure generics and compliance support.
Key Clinical Pearls
- Integrate social work early for patients with anticipated financial or transport barriers.
- Tailor discharge instructions to patient language and literacy levels.
V. Integrating Stewardship into Critical Care Practice
Summary: Effective ICU stewardship combines protocols, PK/PD–driven dosing, rapid diagnostics, and real-time feedback in a multidisciplinary model.
5.1 Core Elements of an ICU Antimicrobial Stewardship Program
- Prospective audit with feedback and formulary restriction/preauthorization.
- Rapid diagnostics and TDM integration to guide de-escalation.
5.2 Incorporating PK/PD Principles into Protocols
- Implement extended-infusion β-lactam pathways and aminoglycoside peak-based dosing.
- Use population PK/Bayesian models for individualized regimens.
5.3 Multidisciplinary Collaboration and Technology Enablers
- Engage ID physicians, pharmacists, microbiology, nursing, and IT.
- Leverage clinical decision support for alerts on ARC, organ dysfunction, and TDM results.
Key Clinical Pearls
- Stewardship interventions must never delay urgent sepsis therapy.
- Real-time dashboards enhance team situational awareness and compliance.
References
- Dellit TH, Owens RC Jr, McGowan JE Jr, et al. IDSA and SHEA guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159–177.
- Pollack LA, Srinivasan A. Core Elements of Hospital Antibiotic Stewardship Programs from the CDC. Clin Infect Dis. 2014;59(Suppl 3):S97–S100.
- Onita A, Ishihara N, Yano T. PK/PD–guided strategies for appropriate antibiotic use in the era of antimicrobial resistance. Antibiotics. 2025;14(1):92.
- Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1–10.
- Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious MRSA infections: a revised consensus guideline. Am J Health-Syst Pharm. 2020;77(11):835–864.
- Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46(6):1127–1153.
- Morales Castro D, Dresser L, Granton J, Fan E. Pharmacokinetic alterations associated with critical illness. Clin Pharmacokinet. 2023;62(2):209–220.
- Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37(3):840–851.
- Pea F, Viale P, Cojutti P, et al. Therapeutic drug monitoring may improve safety of long-term linezolid therapy. J Antimicrob Chemother. 2012;67(9):2034–2042.
- O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. Wellcome Trust; 2016.
- Centers for Disease Control and Prevention. Core Elements of Hospital Antibiotic Stewardship Programs. 2024.
- Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Atlanta, GA; 2013.
- MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev. 2005;18(4):638–656.
- Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis. 2003;36(11):1433–1437.
